Earning Preview: Eli Lilly Q3 revenue is expected to increase by 41.06%, and institutional views are largely bullish
Earnings Agent09:00
Abstract
Eli Lilly will report its quarterly results on October 29, 2026 Pre-MKt; this preview summarizes last quarter’s performance, this quarter’s guidance and forecasts, and the prevailing institutional stance.
Market Forecast
Consensus for Eli Lilly this quarter points to revenue of 22.59 billion US dollars with an estimated year-over-year increase of 41.06%, EBIT of 8.06 billion US dollars with an estimated year-over-year increase of 22.44%, and EPS of 6.94 with an estimated year-over-year increase of 21.91%. The company’s margin framework implied by recent results suggests a gross profit margin near the mid-80% range and a net profit margin near the low-30% range year over year; adjusted EPS is expected to grow roughly in line with revenue expansion driven by incretin demand.
Management’s focus remains on execution in the obesity and diabetes franchises, supported by continued capacity expansions and new launches; pipeline contributions are building from newly launched therapies. The most promising segment is tirzepatide-based incretins (including Zepbound for obesity and Mounjaro for type 2 diabetes), with combined recent-quarter revenue of 14.87 billion US dollars and rapid year-over-year revenue momentum.
Last Quarter Review
Eli Lilly delivered revenue of 22.97 billion US dollars, a gross profit margin of 85.78%, GAAP net profit attributable to the parent company of 7.10 billion US dollars, a net profit margin of 30.88%, and adjusted EPS of 8.38, with year-over-year growth for revenue of 47.67% and adjusted EPS of 32.81%. Quarter on quarter, GAAP net profit declined by 4.07%.
A key highlight was operating leverage from scale-up in incretins, which supported EBIT of 9.81 billion US dollars and solid cash generation. Main business performance was led by tirzepatide at 9.94 billion US dollars and Zepbound at 4.93 billion US dollars, supplemented by new launches such as Ebglyss, Jaypirca, and Kisunla.
Current Quarter Outlook
Main commercial engine: incretin portfolio execution and supply
The core driver this quarter is the incretin portfolio centered on tirzepatide across diabetes and obesity indications. The previous quarter’s revenue base of 14.87 billion US dollars between Mounjaro and Zepbound underscores the scale of demand and the sensitivity of results to production throughput. Investors will focus on the cadence of fill rates, pharmacy inventory normalization, and the mix shift between obesity and diabetes prescriptions, because pricing dynamics and payer coverage can affect realized net price per script. Any update on manufacturing debottlenecking, including device assembly and API yields, will directly influence revenue conversion and gross margin resiliency near the mid-80% range.
Fast-growing launches and breadth beyond incretins
Secondary contributors include new specialty launches such as Ebglyss, Jaypirca, Omvoh, and the Alzheimer’s therapy Kisunla. While each remains smaller in absolute dollars (collectively below 1.00 billion US dollars last quarter), they offer diversified top-line streams and potential upside via label expansions and geographic rollouts. The quarter’s narrative will weigh early uptake curves, discontinuation rates, and access wins; even moderate outperformance here can add incremental hundreds of millions of US dollars to revenue over time and reinforce multi-year EBIT durability.
Stock price swing factors this quarter
Three forces may define the share reaction on October 29, 2026. First, supply commentary for tirzepatide and any quantified capacity steps for 2026–2027 will frame the path for revenue scaling and EPS leverage. Second, obesity market dynamics—competitor promotional activity, formulary positioning, and real-world adherence—could influence both volume growth and gross-to-net. Third, pipeline and lifecycle updates, including additional indications, pediatric studies, and device enhancements, may shape medium-term forecasts even if near-term P&L effects are limited; clearer visibility typically supports valuation stability when headline growth is already elevated.
Analyst Opinions
Across the past six months of coverage, the majority of institutional commentary is bullish, emphasizing sustained demand for incretins, favorable capacity visibility, and above-consensus operating leverage. Analysts highlighting upside scenarios generally point to the 41.06% year-over-year revenue estimate as attainable given last quarter’s 47.67% growth and the breadth of prescription momentum. Representative views from well-followed research desks characterize Eli Lilly as poised to exceed revenue and maintain a high-80s gross margin corridor if supply continues to loosen, while acknowledging that quarter-to-quarter volatility in fulfillment could affect EPS cadence. The prevailing opinion is that upside risk centers on higher-than-modeled Zepbound volumes and a constructive payer mix, with particular attention to incremental capacity commentary and any updates on the Alzheimer’s rollout traction.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
